Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia

Inclusion Criteria:

primary refractory or relapsed AML
confirmed diagnosis of AML (de novo or secondary) as defined by WHO classification (Vardiman 2002)
aged at least 18 years

Exclusion Criteria:

initial diagnosis of acute promyelocytic leukemia as defined by French-American-British criteria (Bennett 1976)
patient in blast crisis stage of chronic myeloid leukemia
received high-dose cytarabine (total cumulative dose of >6g/m sq)in last 6 months
interval of <6 months between first onset of last complete remission and current relapse
those with primary refractory leukemia who have received more than three previous induction cycles
relapsed patients who have received more than three previous treatment regimens